RNA Interference against ATP as a Gene Therapy Approach for Prostate Cancer.


Journal

Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791

Informations de publication

Date de publication:
02 10 2023
Historique:
medline: 3 10 2023
pubmed: 21 9 2023
entrez: 21 9 2023
Statut: ppublish

Résumé

Chemotherapeutic agents targeting energy metabolism have not achieved satisfactory results in different types of tumors. Herein, we developed an RNA interference (RNAi) method against adenosine triphosphate (ATP) by constructing an interfering plasmid-expressing ATP-binding RNA aptamer, which notably inhibited the growth of prostate cancer cells through diminishing the availability of cytoplasmic ATP and impairing the homeostasis of energy metabolism, and both glycolysis and oxidative phosphorylation were suppressed after RNAi treatment. Further identifying the mechanism underlying the effects of ATP aptamer, we surprisingly found that it markedly reduced the activity of membrane ionic channels and membrane potential which led to the dysfunction of mitochondria, such as the decrease of mitochondrial number, reduction in the respiration rate, and decline of mitochondrial membrane potential and ATP production. Meanwhile, the shortage of ATP impeded the formation of lamellipodia that are essential for the movement of cells, consequently resulting in a significant reduction of cell migration. Both the downregulation of the phosphorylation of AMP-activated protein kinase (AMPK) and endoplasmic reticulum kinase (ERK) and diminishing of lamellipodium formation led to cell apoptosis as well as the inhibition of angiogenesis and invasion. In conclusion, as the first RNAi modality targeting the blocking of ATP consumption, the present method can disturb the respiratory chain and ATP pool, which provides a novel regime for tumor therapies..

Identifiants

pubmed: 37733628
doi: 10.1021/acs.molpharmaceut.3c00587
doi:

Substances chimiques

Adenosine Triphosphate 8L70Q75FXE

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5214-5225

Auteurs

Shuangya Chen (S)

School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325030, China.

Jisheng Ma (J)

School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325030, China.

Yunbei Xiao (Y)

Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325030, China.

Dongyan Zhou (D)

School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325030, China.

Ping He (P)

School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325030, China.

Yajing Chen (Y)

School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325030, China.

Xiaolu Zheng (X)

School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325030, China.
Pharmaceutical Department, Jinhua Central Hospital, Jinhua, Zhejiang 321000, China.

Hui Lin (H)

School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325030, China.

Feng Qiu (F)

School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325030, China.

Yuying Yuan (Y)

School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325030, China.

Jiaben Zhong (J)

School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, Guangdong 510006, China.

Xiaokun Li (X)

School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325030, China.

Xuebo Pan (X)

School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325030, China.

Zhiyuan Fang (Z)

School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, Guangdong 510006, China.

Cong Wang (C)

School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325030, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH